Medium-sized DongKwang Pharm successfully avoids KRW 10 billion ‘Cancidas’ patent

A medium pharmaceutical company DongKwang Pharmaceutical raised a chance for the early launch of Cancidas(caspofungin acetate, MSD Korea), antifungal, through avoiding its patent alone.

Since it is the patent other companies are also struggling with even in the U.S., particularly, the result has been highly evaluated.

Cancidas, an antifungal injection, was raised in sales because it has been ...